GIP and obesity due to melanocortin 4 receptor deficiency: Additionally, given the promise of the dual GIP/GLP-1 agonist tirzepatide for the treatment of obesity in people with T2D, further trials exploring cardiovascular outcomes with this drug would be welcome to support its use in routine clinical practice.